FDA Approved Combination Treatment for Acute Myeloid Leukemia (AML)

The United States Food and Drug Administration has recently approved the use of Midostaurin (Rydapt) drug along with chemotherapy for treating patients with acute myeloid leukemia (AML), with a specific gene mutation called FLT3 (FMS-like tyrosine kinase 3).
Email bookmark
Font : A-A+

Related Links